Vertex Pharmaceuticals (NASDAQ: VRTX) might be one of those special cases. Should you buy Vertex stock hand over fist before ...

Vertex Pharmaceuticals Inc. closed 19.80% below its 52-week high of $519.88, which the company reached on November 8th.

HHS challenges Vertex Pharmaceuticals' fertility services program, alleging violations of anti-kickback laws linked to its ...

The most recent trading session ended with Vertex Pharmaceuticals (VRTX) standing at $416.96, reflecting a -1.72% shift from the previouse trading day's closing. The stock's performance was behind the ...

It can generate billions in revenue from both acute and possibly chronic pain. If approved, it would give Vertex ...

Analysis of the S&P 500 health care sector's performance, quant ratings of top companies, and expert opinions on future ...

Keith Speights has positions in Vertex Pharmaceuticals. The Motley Fool has positions in and recommends Vertex Pharmaceuticals. The Motley Fool has a disclosure policy. Why This Beaten-Down Growth ...

Short interest is the number of shares that have been sold short but have not yet been covered or closed out. Short selling ...

周二，RBC Capital Markets调整了Vertex Pharmaceuticals Incorporated (NASDAQ:VRTX)的目标价，从之前的400美元略微上调至401美元。该公司维持对这家生物科技公司股票的"行业表现"评级，目前股价为404.07美元。根据 InvestingPro 分析，该股票的交易价格略高于其公允价值，分析师目标价范围在325美元至602美元之间。

Vertex Pharmaceuticals Inc. closed 18.39% short of its 52-week high of $519.88, which the company reached on November 8th.

Vertex Pharmaceuticals (NASDAQ:VRTX – Get Free Report)‘s stock had its “outperform” rating reaffirmed by stock analysts at ...